$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Money / Business

Johnson & Johnson Pays $2.2 Billion for Ollin

Johnson & Johnson announced a definitive agreement on Monday, November 16, 2026, to acquire Ollin Biosciences for $2.2 billion upfront plus up to about $1.125 billion in milestone payments, and Blackstone Life Sciences will pay Johnson & Johnson $750 million over several years to fund the Phase 3 trial of Ollin's eye drug OLN324.

TML Markets DeskNov 17, 7:27 AM ET · 2 min read

Edited and fact-checked by Stephen Sprague

Johnson & Johnson headquarters in New Brunswick, New Jersey (archive). The company announced the Ollin acquisition from New Brunswick on November 16, 2026. Photo: ekem, public domain, via Wikimedia Commons.
Summary

The headline price is $2.2 billion in cash now and up to $1.125 billion later if the drug performs. The unusual part is the third pile. Blackstone, not Johnson & Johnson, funds the Phase 3 program, and it gets royalties if the drug sells.

Tap a passage. React to the part that matters.

Johnson & Johnson will pay $2.2 billion upfront for Ollin Biosciences, a clinical-stage company with one late-stage eye drug. Ollin has no product on the market.

The total breaks into three piles, and only the first one is certain. Pile one is the $2.2 billion upfront payment for Ollin itself. Pile two is up to approximately $1.125 billion in additional regulatory and commercial milestone payments, money Ollin's shareholders receive only if OLN324 clears the regulators and sells. Pile three is not Johnson & Johnson's money at all. Blackstone Life Sciences will pay Johnson & Johnson a total of $750 million over multiple years to fully fund the Phase 3 development of OLN324, contingent on the acquisition closing.

Blackstone does not write that check for free. In return it becomes eligible for certain regulatory and sales milestone payments plus single-digit royalties on the drug. The structure moves the cost of the pivotal trial off Johnson & Johnson's books and puts a share of the trial's risk on an outside investor, which keeps a slice of the upside if the drug works.

The asset is OLN324, an investigational bispecific antibody in Phase 3. It targets two pathways in retinal disease at once, vascular endothelial growth factor and angiopoietin-2. The drug uses a small protein format the company calls a minibody, with high angiopoietin-2 potency, and it is designed to control retinal fluid in wet age-related macular degeneration and diabetic macular edema. Johnson & Johnson says those two conditions together affect more than 40 million people worldwide and are leading causes of vision loss.

Four office chairs in a rowFor businessesAmazon Business is Amazon’s purchasing store for companies, with business accounts and quantity ordering.Register with Amazon Business

Kip Connor, the company's ophthalmology disease area leader, said the drug has the potential to achieve stronger and more sustained disease control and could allow more time between treatments. That is the commercial bet in one sentence. Retinal drugs are given by injection into the eye, and a drug that holds fluid down longer between injections takes share from the ones that do not.

The transaction is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions. Johnson & Johnson has not yet said how it will account for the deal. The company says the accounting treatment will be communicated on or before the close, which is also when the Blackstone funding agreement takes effect.

What Ollin's shareholders actually bank is the $2.2 billion. The other $1.125 billion is a schedule of ifs tied to approvals and sales that have not happened, for a drug that has not finished its Phase 3 trial. The $750 million from Blackstone is real money with a defined job, and its job is to find out whether the ifs pay.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.